Recombinant west nile virus vaccine adjuvanted with SLA-LSQ

Ended Definitive Contract Awarded Last action

Contract number
75N93022C00034
Awardee
Awarding agency
Obligated
$2,997,218

Award facts

Opportunity
  • PHS202201 Solicitation number
Contract value 100% obligated
$2,997,218.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Honolulu, HI 96817, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $2,997,218

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a definitive contract valued at $2,997,218 to Hawaii Biotech, Inc. to provide Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ under a total small business set aside. The contract is a firm fixed price agreement that will run from July 5, 2022 through July 5, 2025 with performance taking place in Honolulu, Hawaii.

Quick answers

Who was awarded contract 75N93022C00034?

75N93022C00034 was awarded to Hawaii Biotech, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 5, 2022.

How much is contract 75N93022C00034 worth?

The government has obligated $2,997,218 on 75N93022C00034.

Was contract 75N93022C00034 competed?

The extent of competition for 75N93022C00034 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award